Somewhat Positive News Coverage Somewhat Unlikely to Impact Intersect ENT (XENT) Share Price
Media headlines about Intersect ENT (NASDAQ:XENT) have trended somewhat positive on Wednesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intersect ENT earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.8577303478311 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- A Reversal for Intersect ENT, Inc. (XENT) Is Not Near. The Stock Reaches 52-Week High Today – The Louisville Oracle (louisvilleoracle.com)
- Intersect ENT, Inc. (XENT) Just Reaches 52-Week High? – Thе Malibu Rеpоrt (malibureport.com)
- Zacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Earnings of -$0.23 Per Share (americanbankingnews.com)
- Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock (americanbankingnews.com)
Shares of Intersect ENT (NASDAQ XENT) traded down $0.10 during mid-day trading on Wednesday, reaching $38.65. The company had a trading volume of 163,368 shares, compared to its average volume of 268,627. The firm has a market cap of $1,159.41, a price-to-earnings ratio of -67.81 and a beta of 0.80. Intersect ENT has a twelve month low of $14.90 and a twelve month high of $39.30.
XENT has been the topic of a number of research analyst reports. BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. JPMorgan Chase & Co. raised Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 target price on shares of Intersect ENT in a report on Monday, December 11th. Zacks Investment Research raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Finally, Guggenheim reissued a “buy” rating on shares of Intersect ENT in a report on Thursday, March 1st. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $33.38.
In other Intersect ENT news, insider Lisa D. Earnhardt sold 10,685 shares of Intersect ENT stock in a transaction on Friday, December 15th. The stock was sold at an average price of $31.87, for a total value of $340,530.95. Following the completion of the transaction, the insider now owns 487,868 shares in the company, valued at approximately $15,548,353.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gwen R. Carscadden sold 10,000 shares of Intersect ENT stock in a transaction on Friday, January 12th. The shares were sold at an average price of $34.35, for a total value of $343,500.00. Following the completion of the transaction, the insider now owns 13,856 shares of the company’s stock, valued at approximately $475,953.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,310 shares of company stock worth $4,660,238. 13.70% of the stock is owned by insiders.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.